FY2024 Earnings Estimate for DWTX Issued By Zacks Small Cap

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) – Equities research analysts at Zacks Small Cap issued their FY2024 EPS estimates for Dogwood Therapeutics in a research note issued to investors on Tuesday, March 18th. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings per share of ($6.43) for the year. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. Zacks Small Cap also issued estimates for Dogwood Therapeutics’ Q4 2024 earnings at ($1.49) EPS, FY2025 earnings at ($4.57) EPS and FY2026 earnings at ($1.90) EPS.

Dogwood Therapeutics Stock Down 7.3 %

Shares of DWTX stock opened at $6.33 on Friday. The company has a market cap of $8.43 million, a P/E ratio of -0.97 and a beta of 2.07. Dogwood Therapeutics has a one year low of $1.62 and a one year high of $29.28. The company’s fifty day moving average price is $7.28.

Institutional Trading of Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Geode Capital Management LLC bought a new position in Dogwood Therapeutics, Inc. (NASDAQ:DWTX) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 10,933 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned about 0.82% of Dogwood Therapeutics as of its most recent SEC filing. 9.05% of the stock is currently owned by institutional investors and hedge funds.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.